MA46611B1 - Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs - Google Patents
Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifsInfo
- Publication number
- MA46611B1 MA46611B1 MA46611A MA46611A MA46611B1 MA 46611 B1 MA46611 B1 MA 46611B1 MA 46611 A MA46611 A MA 46611A MA 46611 A MA46611 A MA 46611A MA 46611 B1 MA46611 B1 MA 46611B1
- Authority
- MA
- Morocco
- Prior art keywords
- psychiatric
- treatment
- cognitive disorders
- imidazopyrazinones
- schizophrenia
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title abstract 7
- 208000020016 psychiatric disease Diseases 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 4
- 238000002648 combination therapy Methods 0.000 title 1
- MPWOBEOETVOESI-UHFFFAOYSA-N imidazo[4,5-b]pyrazin-2-one Chemical class N1=CC=NC2=NC(=O)N=C21 MPWOBEOETVOESI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000028698 Cognitive impairment Diseases 0.000 abstract 3
- 201000000980 schizophrenia Diseases 0.000 abstract 3
- 101100243084 Dictyostelium discoideum pdsA gene Proteins 0.000 abstract 2
- 101100243086 Schizosaccharomyces pombe (strain 972 / ATCC 24843) cgs2 gene Proteins 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 238000011284 combination treatment Methods 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201600659 | 2016-10-28 | ||
| PCT/EP2017/077497 WO2018078038A1 (en) | 2016-10-28 | 2017-10-26 | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA46611A MA46611A (fr) | 2019-09-04 |
| MA46611B1 true MA46611B1 (fr) | 2020-08-31 |
Family
ID=60186299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46611A MA46611B1 (fr) | 2016-10-28 | 2017-10-26 | Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10905688B2 (ru) |
| EP (1) | EP3532064B1 (ru) |
| JP (1) | JP2019536762A (ru) |
| KR (1) | KR20190075068A (ru) |
| CN (1) | CN109803658A (ru) |
| AR (1) | AR109991A1 (ru) |
| AU (1) | AU2017350473A1 (ru) |
| BR (1) | BR112018013247A2 (ru) |
| CA (1) | CA3041607A1 (ru) |
| CL (1) | CL2019001091A1 (ru) |
| CO (1) | CO2019002909A2 (ru) |
| CY (1) | CY1123396T1 (ru) |
| DK (1) | DK3532064T3 (ru) |
| ES (1) | ES2816005T3 (ru) |
| HR (1) | HRP20201326T1 (ru) |
| HU (1) | HUE050403T2 (ru) |
| IL (1) | IL265635A (ru) |
| LT (1) | LT3532064T (ru) |
| MA (1) | MA46611B1 (ru) |
| ME (1) | ME03821B (ru) |
| MX (1) | MX2019004763A (ru) |
| PL (1) | PL3532064T3 (ru) |
| PT (1) | PT3532064T (ru) |
| RS (1) | RS60716B1 (ru) |
| RU (1) | RU2019109039A (ru) |
| SG (1) | SG11201903770UA (ru) |
| SI (1) | SI3532064T1 (ru) |
| SM (1) | SMT202000440T1 (ru) |
| WO (1) | WO2018078038A1 (ru) |
| ZA (1) | ZA201902091B (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| EP3529250B1 (en) | 2016-10-18 | 2023-12-06 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| AU2017350473A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| AU2017350477A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| CA3090219A1 (en) | 2018-02-01 | 2019-08-08 | Japan Tobacco Inc. | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB973361A (en) | 1960-05-11 | 1964-10-28 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| JP2006525966A (ja) | 2003-05-09 | 2006-11-16 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | ６−シクリルメチル−および６−アルキルメチル置換ピラゾロピリミジン類 |
| WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
| EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| EP2089034A4 (en) | 2006-12-05 | 2010-07-28 | Intra Cellular Therapies Inc | NEW USES |
| SI2152712T1 (sl) | 2007-05-11 | 2012-03-30 | Pfizer | Amino heterociklične spojine |
| WO2009068320A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| MX2011002340A (es) | 2008-09-08 | 2011-04-04 | Boehringer Ingelheim Int | Pirazolopirimidinas y su uso para el tratamiento de trastornos del snc. |
| JP5813511B2 (ja) | 2008-12-06 | 2015-11-17 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| EP4218794A3 (en) | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
| EP2575817A4 (en) | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| DK2603523T3 (en) | 2010-08-12 | 2016-03-21 | Lilly Co Eli | ANTI-N3pGlu-AMYLOIDBETAPEPTIDANTISTOFFER AND USES THEREOF |
| AR083058A1 (es) | 2010-09-20 | 2013-01-30 | Envivo Pharmaceuticals Inc | Compuestos de estructura de imidazotriazinona |
| WO2012040048A2 (en) | 2010-09-21 | 2012-03-29 | Schering Corporation | Triazolopyrazinones as p2x7 receptor antagonists |
| JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| JOP20120083B1 (ar) * | 2011-04-05 | 2021-08-17 | Otsuka Pharma Co Ltd | توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| JP6051210B2 (ja) | 2011-06-10 | 2016-12-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| EP2906562B1 (en) | 2011-10-10 | 2016-10-05 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
| CN107082783B (zh) | 2012-01-26 | 2019-03-22 | H.隆德贝克有限公司 | 具有咪唑并三嗪酮骨架的pde9抑制剂 |
| BR112014031730B1 (pt) | 2012-06-18 | 2023-05-16 | Dart Neuroscience (Cayman) Ltd | Compostos ou sais farmaceuticamente aceitáveis dos mesmos e seu uso |
| ES2836129T3 (es) | 2013-03-15 | 2021-06-24 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| JP5783297B2 (ja) | 2013-08-06 | 2015-09-24 | 株式会社デンソー | 力学量センサ |
| AU2015220873A1 (en) | 2014-02-19 | 2016-08-11 | H. Lundbeck A/S | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's disease |
| JP5797815B1 (ja) | 2014-06-27 | 2015-10-21 | 細田建設株式会社 | 後施工アンカー及びその施工方法 |
| JP2017527606A (ja) | 2014-09-18 | 2017-09-21 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 三環系誘導体 |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
| MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
| JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
| WO2016147659A1 (en) | 2015-03-16 | 2016-09-22 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic imidazolo derivative |
| TW201643167A (zh) | 2015-04-22 | 2016-12-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之咪唑並三酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| HK1253372A1 (zh) | 2015-08-12 | 2019-06-14 | H‧隆德贝克有限公司 | 作为bace1抑制剂的2-氨基-3-氟-3-(氟甲基)-6-甲基-6-苯基-3，4，5，6-四氢吡啶 |
| CN105254635A (zh) * | 2015-10-30 | 2016-01-20 | 中国药科大学 | 一类咪唑并吡嗪类化合物及其药物组合物和用途 |
| TWI609870B (zh) | 2016-02-12 | 2018-01-01 | 美國禮來大藥廠 | Pde1抑制劑 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| JP2018076285A (ja) | 2016-09-14 | 2018-05-17 | 大日本住友製薬株式会社 | 二環性イミダゾロ誘導体を含む医薬 |
| EP3529250B1 (en) | 2016-10-18 | 2023-12-06 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| AU2017350477A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| AU2017350473A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
-
2017
- 2017-10-26 AU AU2017350473A patent/AU2017350473A1/en not_active Abandoned
- 2017-10-26 PL PL17791080T patent/PL3532064T3/pl unknown
- 2017-10-26 DK DK17791080.9T patent/DK3532064T3/da active
- 2017-10-26 SG SG11201903770UA patent/SG11201903770UA/en unknown
- 2017-10-26 MX MX2019004763A patent/MX2019004763A/es unknown
- 2017-10-26 CN CN201780063182.9A patent/CN109803658A/zh active Pending
- 2017-10-26 HU HUE17791080A patent/HUE050403T2/hu unknown
- 2017-10-26 HR HRP20201326TT patent/HRP20201326T1/hr unknown
- 2017-10-26 RS RS20200975A patent/RS60716B1/sr unknown
- 2017-10-26 WO PCT/EP2017/077497 patent/WO2018078038A1/en not_active Ceased
- 2017-10-26 PT PT177910809T patent/PT3532064T/pt unknown
- 2017-10-26 US US16/345,136 patent/US10905688B2/en not_active Expired - Fee Related
- 2017-10-26 KR KR1020197011509A patent/KR20190075068A/ko not_active Ceased
- 2017-10-26 SM SM20200440T patent/SMT202000440T1/it unknown
- 2017-10-26 LT LTEP17791080.9T patent/LT3532064T/lt unknown
- 2017-10-26 BR BR112018013247A patent/BR112018013247A2/pt not_active Application Discontinuation
- 2017-10-26 JP JP2019522523A patent/JP2019536762A/ja active Pending
- 2017-10-26 EP EP17791080.9A patent/EP3532064B1/en active Active
- 2017-10-26 CA CA3041607A patent/CA3041607A1/en not_active Abandoned
- 2017-10-26 ES ES17791080T patent/ES2816005T3/es active Active
- 2017-10-26 MA MA46611A patent/MA46611B1/fr unknown
- 2017-10-26 RU RU2019109039A patent/RU2019109039A/ru not_active Application Discontinuation
- 2017-10-26 SI SI201730388T patent/SI3532064T1/sl unknown
- 2017-10-26 ME MEP-2020-170A patent/ME03821B/me unknown
- 2017-10-27 AR ARP170102997A patent/AR109991A1/es unknown
-
2019
- 2019-03-26 IL IL265635A patent/IL265635A/en unknown
- 2019-03-27 CO CONC2019/0002909A patent/CO2019002909A2/es unknown
- 2019-04-03 ZA ZA2019/02091A patent/ZA201902091B/en unknown
- 2019-04-22 CL CL2019001091A patent/CL2019001091A1/es unknown
-
2020
- 2020-08-24 CY CY20201100788T patent/CY1123396T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018078038A1 (en) | 2018-05-03 |
| RU2019109039A (ru) | 2020-11-30 |
| IL265635A (en) | 2019-05-30 |
| PL3532064T3 (pl) | 2020-11-16 |
| SI3532064T1 (sl) | 2020-10-30 |
| ME03821B (me) | 2021-04-20 |
| JP2019536762A (ja) | 2019-12-19 |
| EP3532064B1 (en) | 2020-07-29 |
| MX2019004763A (es) | 2019-07-01 |
| DK3532064T3 (da) | 2020-08-24 |
| SG11201903770UA (en) | 2019-05-30 |
| LT3532064T (lt) | 2020-09-25 |
| KR20190075068A (ko) | 2019-06-28 |
| ZA201902091B (en) | 2020-10-28 |
| HRP20201326T1 (hr) | 2020-11-27 |
| AU2017350473A1 (en) | 2019-04-18 |
| BR112018013247A2 (pt) | 2018-12-04 |
| RU2019109039A3 (ru) | 2021-01-29 |
| HUE050403T2 (hu) | 2020-12-28 |
| CL2019001091A1 (es) | 2019-07-05 |
| PT3532064T (pt) | 2020-09-03 |
| CA3041607A1 (en) | 2018-05-03 |
| ES2816005T3 (es) | 2021-03-31 |
| CY1123396T1 (el) | 2021-12-31 |
| EP3532064A1 (en) | 2019-09-04 |
| AR109991A1 (es) | 2019-02-13 |
| RS60716B1 (sr) | 2020-09-30 |
| CO2019002909A2 (es) | 2019-06-19 |
| CN109803658A (zh) | 2019-05-24 |
| US20190282571A1 (en) | 2019-09-19 |
| SMT202000440T1 (it) | 2020-09-10 |
| US10905688B2 (en) | 2021-02-02 |
| MA46611A (fr) | 2019-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46611B1 (fr) | Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs | |
| MA40290A1 (fr) | Agents immunorégulateurs | |
| MA54231A (fr) | Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine | |
| MA52288B1 (fr) | Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci | |
| MA47447B1 (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
| MA39219A1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
| WO2019035864A8 (en) | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS | |
| MA52492B1 (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
| MA43113B1 (fr) | Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci | |
| MA35460B1 (fr) | Composés et compositions en tant qu'inhibiteurs de kinase c-kit | |
| MA44312A (fr) | Anticorps et leurs méthodes d'utilisation | |
| MA38261A1 (fr) | Composes comprenant un noyau polycyclique destines a etre utilises dans le traitement de l'hepatite c (vhc) | |
| MA49947B1 (fr) | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes | |
| MA41179A (fr) | Composés inhibiteurs de parg | |
| MA33053B1 (fr) | Inhibiteurs de la poly(adp-ribose) polymerase (parp) | |
| MA47217A (fr) | Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique | |
| MA42397B1 (fr) | 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b | |
| MA41072A1 (fr) | Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline | |
| MA32131B1 (fr) | Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine | |
| MA58049B1 (fr) | Antagonistes du récepteur du sous-type 2 de la mélanocortine (mc2r) à pipéridine à double substitution gem et leurs utilisations | |
| MA53665B1 (fr) | Agonistes du récepteur farnésoïde x et leurs utilisations | |
| MA41757A (fr) | Transplantation ciblée de mitochondries dans des hépatocytes | |
| MA30037B1 (fr) | Compositions et procedes destines au traitement des troubles du snc | |
| FR3063645B1 (fr) | Acefapc pour le traitement des maladies acetylcholine dependantes | |
| WO2018049003A8 (en) | ANTI-FIBROTIC SIALIDASE INHIBITOR COMPOUNDS AND THEIR METHODS OF USE |